Literature DB >> 3542810

Characterization and biological effects of recombinant human erythropoietin.

J C Egrie, T W Strickland, J Lane, K Aoki, A M Cohen, R Smalling, G Trail, F K Lin, J K Browne, D K Hines.   

Abstract

Human recombinant erythropoietin (rHuEPO) has been purified to apparent homogeneity and compared to purified human urinary erythropoietin (EPO). Both the purified natural and recombinant EPO preparations were characterized in a competition radioimmunoassay (RIA), the exhypoxic polycythemic mouse bioassay, in vitro tissue culture bioassays using bone marrow cells, and by Western analysis. In the immunological and biological activity assays, the rHuEPO shows a dose response which parallels that of the natural hormone. By Western analysis, the recombinant and human urinary EPO migrate identically. Administration of rHuEPO increases the hematocrit of normal mice in a dose-dependent manner. Additionally, the rHuEPO is able to increase the hematocrit of rats made uremic as a result of subtotal nephrectomy. In summary, by all criteria examined, the rHuEPO is biologically active and equivalent to the natural hormone.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3542810     DOI: 10.1016/S0171-2985(86)80101-2

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  33 in total

1.  Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells.

Authors:  M Takeuchi; N Inoue; T W Strickland; M Kubota; M Wada; R Shimizu; S Hoshi; H Kozutsumi; S Takasaki; A Kobata
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

2.  Effect of human recombinant erythropoietin on human hemopoietic progenitor cells in vitro.

Authors:  A Ganser; B Völkers; P Scigalla; D Hoelzer
Journal:  Klin Wochenschr       Date:  1988-03-15

3.  Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.

Authors:  Per Olsson-Gisleskog; Philippe Jacqmin; Juan Jose Perez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Authors:  Sameer Doshi; Wojciech Krzyzanski; Susan Yue; Steven Elliott; Andrew Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

5.  How bio-questionable are the different recombinant human erythropoietin copy products in Thailand?

Authors:  Liem Andhyk Halim; Vera Brinks; Wim Jiskoot; Stefan Romeijn; Kearkiat Praditpornsilpa; Anunchai Assawamakin; Huub Schellekens
Journal:  Pharm Res       Date:  2013-11-21       Impact factor: 4.200

6.  Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies.

Authors:  Richard de Boer; Michael Clemens; Gabor Renczes; Dusan Kotasek; Jana Prausova; Norbert Marschner; Michael Hedenus; Sameer Doshi; Lisa Hendricks; Anders C Österborg
Journal:  Med Oncol       Date:  2010-10-29       Impact factor: 3.064

7.  Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin.

Authors:  C G Winearls
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

8.  Myoblast transfer of human erythropoietin gene in a mouse model of renal failure.

Authors:  Y Hamamori; B Samal; J Tian; L Kedes
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Systemic injection of recombinant human erythropoietin after focal cerebral ischemia enhances oligodendroglial and endothelial progenitor cells in rat brain.

Authors:  Young Jae Kim; Yong-Wook Jung
Journal:  Anat Cell Biol       Date:  2010-06-30

Review 10.  Preoperative erythropoietin in spine surgery.

Authors:  Maria J Colomina; Juan Bagó; Ferran Pellisé; Carmen Godet; Carlos Villanueva
Journal:  Eur Spine J       Date:  2004-06-09       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.